Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Sayegh

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Frontiers in Immunology|August 28, 2023
Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profilesAmeish Govindarajan, Nicholas J Salgia, Haiqing Li, et al.
JAMA Network Open|October 2, 2025
Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 AlterationsMicah Ostrowski, Yeonjung Jo, Chadi Hage Chehade, et al.
The Oncologist|July 11, 2023
Real-World Outcomes of Latinx Versus Non-Latinx Patients Treated With First-Line Immunotherapy for Metastatic Renal-Cell CarcinomaAlexander Chehrazi-Raffle, Sally Leong, Sana Ali, et al.
The Prostate|April 1, 2024
Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive settingGeorges Gebrael, Chadi Hage Chehade, Nicolas Sayegh, et al.
JAMA Network Open|March 31, 2022
Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate CancerRyon P Graf, Virginia Fisher, Janick Weberpals, et al.
Clinical Genitourinary Cancer|July 26, 2023
Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell CarcinomaNazli Dizman, Ameish Govindarajan, Zeynep B Zengin, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2022
Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapyJeffrey Graham, John Connor Wells, Shaan Dudani, et al.
The Oncologist|April 17, 2024
Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimensEddy Saad, Georges Gebrael, Karl Semaan, et al.
Frontiers in Oncology|October 3, 2022
Genomic landscape of advanced prostate cancer patients with <i>BRCA1</i> versus <i>BRCA2</i> mutations as detected by comprehensive genomic profiling of cell-free DNAUmang Swami, Raquel Mae Zimmerman, Roberto H Nussenzveig, et al.
The Prostate|November 16, 2022
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancerChristopher T Su, Emily Nizialek, Jacob E Berchuck, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Frontiers in Immunology|August 28, 2023
Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profilesAmeish Govindarajan, Nicholas J Salgia, Haiqing Li, et al.
JAMA Network Open|October 2, 2025
Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 AlterationsMicah Ostrowski, Yeonjung Jo, Chadi Hage Chehade, et al.
The Oncologist|July 11, 2023
Real-World Outcomes of Latinx Versus Non-Latinx Patients Treated With First-Line Immunotherapy for Metastatic Renal-Cell CarcinomaAlexander Chehrazi-Raffle, Sally Leong, Sana Ali, et al.
The Prostate|April 1, 2024
Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive settingGeorges Gebrael, Chadi Hage Chehade, Nicolas Sayegh, et al.
JAMA Network Open|March 31, 2022
Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate CancerRyon P Graf, Virginia Fisher, Janick Weberpals, et al.
Clinical Genitourinary Cancer|July 26, 2023
Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell CarcinomaNazli Dizman, Ameish Govindarajan, Zeynep B Zengin, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2022
Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapyJeffrey Graham, John Connor Wells, Shaan Dudani, et al.
The Oncologist|April 17, 2024
Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimensEddy Saad, Georges Gebrael, Karl Semaan, et al.
Frontiers in Oncology|October 3, 2022
Genomic landscape of advanced prostate cancer patients with <i>BRCA1</i> versus <i>BRCA2</i> mutations as detected by comprehensive genomic profiling of cell-free DNAUmang Swami, Raquel Mae Zimmerman, Roberto H Nussenzveig, et al.
The Prostate|November 16, 2022
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancerChristopher T Su, Emily Nizialek, Jacob E Berchuck, et al.
Pageof 8